- Trials with a EudraCT protocol (85)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
85 result(s) found for: Line source.
Displaying page 1 of 5.
EudraCT Number: 2020-003908-14 | Sponsor Protocol Number: M-2020-371 | Start Date*: 2021-07-07 | ||||||||||||||||
Sponsor Name:Miltenyi Biomedicine GmbH | ||||||||||||||||||
Full Title: A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diff... | ||||||||||||||||||
Medical condition: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002358-18 | Sponsor Protocol Number: GMED16-001 | Start Date*: 2016-09-14 |
Sponsor Name:Medsenic | ||
Full Title: Phase II study of first line treatment of Chronic Graft versus Host Disease with Arsenic Trioxide | ||
Medical condition: First line treatment of Chronic Graft versus Host Disease in patients having received a first allogeneic stem cell transplantation for a hematological disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001061-83 | Sponsor Protocol Number: 2215-CL-0304 | Start Date*: 2017-07-13 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | |||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with... | |||||||||||||
Medical condition: FMS-like tyrosine kinase 3 (FLT3) / internal tandem duplication (ITD) (FLT3/ITD) acute myeloid leukemia (AML) in first morphologic complete remission (CR1) that has been treated with allogeneic hem... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) PL (Completed) DK (Completed) FR (Ongoing) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016898-14 | Sponsor Protocol Number: BRD 09/6-B | Start Date*: 2010-05-26 | |||||||||||
Sponsor Name:CHU de Nantes | |||||||||||||
Full Title: Phase II study of first line treatment of chronic graft versus host disease with the association of ciclosporine, corticosteroids and Rituximab | |||||||||||||
Medical condition: Chronic graft versus host disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003644-37 | Sponsor Protocol Number: HE6B/16 | Start Date*: 2017-08-01 | |||||||||||
Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG) | |||||||||||||
Full Title: Single-arm phase II study of panitumumab rechallenge in combination with oxaliplatin or irinotecan-based chemotherapy in patients with RAS wild type advanced colorectal cancer. | |||||||||||||
Medical condition: RAS wild type advanced colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) CY (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006323-31 | Sponsor Protocol Number: D1532C00016 | Start Date*: 2009-05-19 | |||||||||||||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||
Full Title: D1532C00016: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line... | |||||||||||||||||||||||
Medical condition: 2nd Line Patients with KRAS Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) BG (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-015744-42 | Sponsor Protocol Number: NA | Start Date*: 2009-12-03 |
Sponsor Name:Oxford Radcliffe Hospitals Trust | ||
Full Title: Randomized open label study of oral versus intravenous antibiotic treatment for bone and joint infections requiring prolonged antibiotic treatment: Preliminary study in a single centre. | ||
Medical condition: Bone and joint infection including; o Osteomyelitis. o Septic arthritis. o Prosthetic joint associated infection o Orthopaedic device associated infection o Discitis/ epidural abscess | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000911-25 | Sponsor Protocol Number: BST-LT-01 | Start Date*: 2019-02-12 | |||||||||||
Sponsor Name:Banc de Sang i Teixits | |||||||||||||
Full Title: A prospective multicenter open, not controlled phase Ib-II clinical trial to assess the safety and immunologic efficacy of virus-specific T lymphocytes from the best donor in receptors of hematopoi... | |||||||||||||
Medical condition: CMV viral infection in an immunocompromised host | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001657-29 | Sponsor Protocol Number: TMC125-C227 | Start Date*: 2006-07-05 |
Sponsor Name:Tibotec Pharmaceuticals Limited | ||
Full Title: A Phase II, randomized, active controlled, open label trial to investigate the efficacy and tolerability of TMC125 in HIV-1 infected subjects, who are PI-naïve and with documented genotypic evidenc... | ||
Medical condition: HIV-1 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003850-15 | Sponsor Protocol Number: CINC280A2201 | Start Date*: 2015-05-08 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) | |||||||||||||
Medical condition: Advanced non-small cell ling cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) ES (Ongoing) NL (Completed) FR (Completed) BE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002124-21 | Sponsor Protocol Number: GINECO-EN105b | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:ARCAGY-GINECO | |||||||||||||
Full Title: Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting: DOMENICA STUDY (GINECO-EN105b/ENGO... | |||||||||||||
Medical condition: Endometrial cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004372-36 | Sponsor Protocol Number: BL-8040.PAC.201 | Start Date*: 2019-05-21 |
Sponsor Name:BioLineRx Ltd. | ||
Full Title: A phase IIa, multicenter, Open-Label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients with Metastatic Pancreatic Cancer, the COMBAT study | ||
Medical condition: Pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002273-11 | Sponsor Protocol Number: 54767414MMY3008 | Start Date*: 2015-03-11 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for Hig... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) NL (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001173-26 | Sponsor Protocol Number: 580299/012,107476 - 477 - 479 - 481 | Start Date*: 2004-10-08 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: Long-term follow-up: A long-term, open, follow-up of the immunogenicity and safety of the vaccine in healthy female subjects vaccinated either pre- or post-menarche in the HPV-012 study. Primary: A... | ||
Medical condition: For active immunization of women from the age of 10 years onwards to prevent persistent HPV-16 and HPV-18 infection and HPV-16 and HPV-18 associated cervical neoplasia. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: DK (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002272-88 | Sponsor Protocol Number: 54767414MMY3007 | Start Date*: 2014-10-20 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed) DE (Completed) BG (Completed) RO (Ongoing) PL (Completed) HR (Completed) GR (Completed) PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000245-39 | Sponsor Protocol Number: BGB-A317-303 | Start Date*: 2018-06-21 | |||||||||||
Sponsor Name:BeiGene Ltd., c/o BeiGene USA Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti−PD1 Antibody) Compared with Docetaxel in Patients with Non−Small Cell Lung Cancer Who H... | |||||||||||||
Medical condition: Previously treated Non−Small Cell Lung Cancer in the second or third line setting. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) LT (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000241-74 | Sponsor Protocol Number: CNTO148AKS3001 | Start Date*: 2014-12-30 | |||||||||||
Sponsor Name:Janssen Biologics, BV | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Ankylosing Spondylitis | |||||||||||||
Medical condition: Ankylosing spondylitis (AS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000242-30 | Sponsor Protocol Number: CNTO148PSA3001 | Start Date*: 2014-12-29 | |||||||||||
Sponsor Name:Janssen Biologics, BV | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Psoriatic Arthritis | |||||||||||||
Medical condition: Psoriatic Arthritis (PsA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LT (Completed) ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000538-78 | Sponsor Protocol Number: INCB39110-301 | Start Date*: 2017-09-14 | ||||||||||||||||||||||||||
Sponsor Name:Incyte Corporation | ||||||||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host Disease | ||||||||||||||||||||||||||||
Medical condition: Male or female, 18 years of age or older who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) BE (Completed) AT (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) GR (Completed) FI (Completed) IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003385-14 | Sponsor Protocol Number: AROAAT2001 | Start Date*: 2019-08-06 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficie... | |||||||||||||
Medical condition: alpha-1 antitrypsin deficiency (AATD)-associated liver disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) SE (Completed) ES (Restarted) GB (GB - no longer in EU/EEA) PT (Completed) NL (Ongoing) DE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
